Although Parkinson’s disease and Lewy body dementia still lack definitive cures, early detection and treatment of depressive symptoms can markedly enhance patients’ wellbeing as these conditions progress.
A recent investigation appearing in General Psychiatry offers the most comprehensive longitudinal data yet, showing that depression often emerges before the clinical onset of Parkinson’s disease (PD) or Lewy body dementia (LBD) and stays elevated for years afterward.
Utilising nationwide Danish health registers, researchers performed a retrospective case‑control analysis of 17,711 individuals diagnosed with PD or LBD between 2007 and 2019. Each case was matched with control participants of comparable age and sex who suffered from other chronic ailments such as rheumatoid arthritis, chronic kidney disease, or osteoporosis.
The analysis revealed a consistent trend: people who later developed PD or LBD experienced depression more frequently and at an earlier stage than those with other long‑term conditions. The risk of depressive episodes climbed steadily in the years leading up to diagnosis, reaching its apex roughly three years before the neurological disease was confirmed. Even after diagnosis, the prevalence of depression remained higher in the PD and LBD groups compared with the control cohorts.
Crucially, this pattern could not be fully attributed to the psychological strain of living with a disabling illness. Other chronic diseases that also cause functional limitation did not show the same pronounced rise in depression risk, suggesting that early neurodegenerative changes in the brain may trigger mood disturbances.
The association was particularly strong for Lewy body dementia, where depressive rates surpassed those observed in Parkinson’s disease both before and after diagnosis. Researchers speculate that variations in disease trajectory and neurotransmitter alterations may underlie this difference.
Overall, while curative therapies remain elusive, recognizing and managing depression early offers a practical avenue to improve quality of life for individuals facing these neurodegenerative disorders.